ATYPICAL RESPONDERS LANDSCAPE REVIEW ∙ OCTOBER, 2017 47 69. Johnson, S.B., et al., Use of Alternative Medicine for Cancer and Its Impact on Survival. J Natl Cancer Inst, 2018. 110(1). 70. Lin, Y., et al., High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer. J Cancer, 2015. 6(11): p. 1130-9. 71. Hong, K.J., M.C. Hsu, and W.C. Hung, RECK impedes DNA repair by inhibiting the erbB/JAB1/ Rad51 signaling axis and enhances chemosensitivity of breast cancer cells. Am J Cancer Res, 2015. 5(8): p. 2422-30. 72. Zhang, H.D., et al., MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel. Biochem Biophys Res Commun, 2015. 465(4): p. 702-13. 73. Mohseni, M., et al., MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. Proc Natl Acad Sci U S A, 2014. 111(49): p. 17606-11. 74. Sparano, J.A., et al., Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med, 2015. 75. Piccart M., R.E., van’ t Veer L., Slaets L., Delaloge S., Viale G., Pierga J.Y., Vuylsteke P., Brain E., Vrijaldenhoven S., Neijenhuis P., Coudert B., Smilde T., Gil M., Thompson A., Rubio I., Passalaqua R., Matos E., Nitz U., Delorenzi M., Thomas G., Goulioti T., Straehle C., Tryfonidis K., Bogaerts J., Cardoso F., on behalf of TRANSBIG consortium and MINDACT investigators. , Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, 2016. 76. Taniguchi, K., et al., Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res, 2011. 17(24): p. 7808-15. 77. Diehl, F., et al., Circulating mutant DNA to assess tumor dynamics. Nat Med, 2008. 14(9): p. 985-990. 78. Lee, J.M., et al., A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab Invest, 2013. 93(5): p. 528- 42. 79. Su, Y., Cancer Chemosensitivity Testing: Review. Journal of Cancer Therapy, 2014. 5: p. 672- 679. 80. Arienti, C., et al., Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. J Transl Med, 2011. 9: p. 94.